% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Schultz:259715,
author = {Schultz, Stephanie A and Shirzadi, Zahra and Schultz, Aaron
P and Liu, Lei and Fitzpatrick, Colleen D and McDade, Eric
and Barthelemy, Nicolas R and Renton, Alan and Esposito,
Bianca and Joseph-Mathurin, Nelly and Cruchaga, Carlos and
Chen, Charles D and Goate, Alison and Allegri, Ricardo
Francisco and Benzinger, Tammie L S and Berman, Sarah and
Chui, Helena C and Fagan, Anne M and Farlow, Martin R and
Fox, Nick C and Gordon, Brian A and Day, Gregory S and
Graff-Radford, Neill R and Hassenstab, Jason J and Hanseeuw,
Bernard J and Hofmann, Anna and Jack, Clifford R and Jucker,
Mathias and Karch, Celeste M and Koeppe, Robert A and Lee,
Jae-Hong and Levey, Allan I and Levin, Johannes and Martins,
Ralph N and Mori, Hiroshi and Morris, John C and Noble,
James and Perrin, Richard J and Rosa-Neto, Pedro and
Salloway, Stephen P and Sanchez-Valle, Raquel and Schofield,
Peter R and Xiong, Chengjie and Johnson, Keith A and
Bateman, Randall J and Sperling, Reisa A and Chhatwal,
Jasmeer P},
collaboration = {Investigators, Dominantly Inherited Alzheimer Network},
title = {{L}ocation of pathogenic variants in {PSEN}1 impacts
progression of cognitive, clinical, and neurodegenerative
measures in autosomal-dominant {A}lzheimer's disease.},
journal = {Aging cell},
volume = {22},
number = {8},
issn = {1474-9718},
address = {Oxford [u.a.]},
publisher = {Wiley-Blackwell},
reportid = {DZNE-2023-00787},
pages = {e13871},
year = {2023},
abstract = {Although pathogenic variants in PSEN1 leading to
autosomal-dominant Alzheimer disease (ADAD) are highly
penetrant, substantial interindividual variability in the
rates of cognitive decline and biomarker change are observed
in ADAD. We hypothesized that this interindividual
variability may be associated with the location of the
pathogenic variant within PSEN1. PSEN1 pathogenic variant
carriers participating in the Dominantly Inherited Alzheimer
Network (DIAN) observational study were grouped based on
whether the underlying variant affects a transmembrane (TM)
or cytoplasmic (CY) protein domain within PSEN1. CY and TM
carriers and variant non-carriers (NC) who completed
clinical evaluation, multimodal neuroimaging, and lumbar
puncture for collection of cerebrospinal fluid (CSF) as part
of their participation in DIAN were included in this study.
Linear mixed effects models were used to determine
differences in clinical, cognitive, and biomarker measures
between the NC, TM, and CY groups. While both the CY and TM
groups were found to have similarly elevated Aβ compared to
NC, TM carriers had greater cognitive impairment, smaller
hippocampal volume, and elevated phosphorylated tau levels
across the spectrum of pre-symptomatic and symptomatic
phases of disease as compared to CY, using both
cross-sectional and longitudinal data. As distinct portions
of PSEN1 are differentially involved in APP processing by
γ-secretase and the generation of toxic β-amyloid species,
these results have important implications for understanding
the pathobiology of ADAD and accounting for a substantial
portion of the interindividual heterogeneity in ongoing ADAD
clinical trials.},
keywords = {Male / Humans / Alzheimer Disease: genetics / Alzheimer
Disease: metabolism / Cross-Sectional Studies / Amyloid
beta-Peptides: genetics / Amyloid beta-Peptides: metabolism
/ Biomarkers / Presenilin-1: genetics / Cognition / Mutation
/ Female / Adult / Brain: metabolism / Brain: pathology /
Positron-Emission Tomography / Magnetic Resonance Imaging /
Presenilin-1: chemistry / Presenilin-1: metabolism /
Alzheimer Disease: pathology / tau Proteins: metabolism /
Longitudinal Studies / PSEN1 (Other) / tau Proteins (NLM
Chemicals) / PSEN1 (Other) / Presenilin-1 (Other) /
Autosomal dominant Alzheimer disease (ADAD) (Other) /
heterogeneity (Other) / neurodegeneration (Other) / Amyloid
beta-Peptides (NLM Chemicals) / Biomarkers (NLM Chemicals) /
Presenilin-1 (NLM Chemicals) / PSEN1 protein, human (NLM
Chemicals) / Presenilin-1 (Other)},
cin = {AG Gasser / AG Jucker / AG Levin / Clinical Research
(Munich)},
ddc = {610},
cid = {I:(DE-2719)1210000 / I:(DE-2719)1210001 /
I:(DE-2719)1111016 / I:(DE-2719)1111015},
pnm = {353 - Clinical and Health Care Research (POF4-353) / 352 -
Disease Mechanisms (POF4-352)},
pid = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-352},
experiment = {EXP:(DE-2719)DIAN-20090101},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37291760},
pmc = {pmc:PMC10410059},
doi = {10.1111/acel.13871},
url = {https://pub.dzne.de/record/259715},
}